VeriSign, Inc.

VRSN·NasdaqGS·Technology
Compare
318.03+4.15 (+1.32%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
Pre-market320.30+2.27 (+0.71%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close313.88
Open313.07
Day range311.47324.21
52-week range208.86324.21
Off day high−1.90%
Off 52-week high−1.90%
Volume1.44M
Avg. volume (3M)853.31K
Market cap28.53B
EPS (TTM)9.29
Forward P/E29.01
P/E ratio (TTM)34.23
Dividend yield1.02% (3.24)
Beta (5Y)0.67
Shares outstanding89.70M
Short interest2.49% of float
Earnings dateOct 22, 2026
Analyst target339.60
Profit margin49.07%

Against its peers

Compare in full ›
VRSN VERTOZ.NS GDDY ODYSSEY.BO CCSI IIIV
Market cap 28.53B 3.01B 14.98B 675.15M 681.32M 661.57M
P/E (TTM) 34.2 11.0 16.3 18.3 7.5 65.6
Forward P/E 29.0 — 10.5 11.2 6.1 15.6
Price/book -12.5 1.4 -104.2 1.1 16.4 1.2
Dividend yield 1.02% 0.32% — 2.15% — —
1-year change +28.62% −54.84% −14.76% −44.78% +21.47% −39.75%
Today +1.32% +11.80% +4.29% −8.81% +2.99% +4.85%

The closest companies by business and industry (Software - Infrastructure). Prices may be delayed up to 15 min.

Latest news

All VRSN news ›
MarketBeat·

VeriSign (NASDAQ:VRSN) CEO Sells $1,029,567.00 in Stock

D James Bidzos also recently made the following trade(s): The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 24th. Investors of record on Tuesday, November 17th will be paid a $0.81 dividend.…

TNW | Business·Negative

Why are premium domains so expensive?

A normal .com costs about $11 a year to register. The best names can sell for millions. Here is why. Premium domains are expensive because each name exists only once, and short, memorable ones are long gone. Registries and owners price…

Stock Titan·Positive

VeriSign officer proposes $989K sale of 3,256 shares

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue…

Stock Titan·Positive

VeriSign’s Danny R. McPherson sells 3,256 shares

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ReconAfrica Announces Grant of Stock Options to New Director Palantir…

From the 4Search news index, newest first.

In the news

77mentions in 30 days
64with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 77 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance